Jump to content

Treatment as prevention: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m bold type
added section
Tags: nowiki added Visual edit
Line 44: Line 44:


Additionally, the window of time between initial infection and first getting tested is too large in some areas, meaning that people with HIV have a higher chance of passing along the virus while their viral load is high, even if they do eventually seek TasP.<ref name=":04" /> Even once TasP is initiated, its success depends on adherence to the treatment. If interrupted, the more sensitive strains of HIV become suppressed, while leaving the more resistant and harder to treat strains to become more dominant.<ref>AIDSinfo (2014) '[http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents]'</ref> Even in areas where access to treatment is fairly eased, adherence has emerged as an issue.
Additionally, the window of time between initial infection and first getting tested is too large in some areas, meaning that people with HIV have a higher chance of passing along the virus while their viral load is high, even if they do eventually seek TasP.<ref name=":04" /> Even once TasP is initiated, its success depends on adherence to the treatment. If interrupted, the more sensitive strains of HIV become suppressed, while leaving the more resistant and harder to treat strains to become more dominant.<ref>AIDSinfo (2014) '[http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents]'</ref> Even in areas where access to treatment is fairly eased, adherence has emerged as an issue.

== Short-Term and Long-Term Solutions ==

=== Global Fund ===
In 2002, [[The Global Fund to Fight AIDS, Tuberculosis and Malaria|The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund)]]<nowiki/>was a financial initiative developed to raise and provide funding to the developing world in an attempt to enhance their care and treatment programs for individuals who are living with HIV/AIDS, TB and malaria. For the international organization to be successful, developed countries must work in conjunction with third-world countries, private organizations, civil society and afflicted communities to ease the impact of the epidemics. In an attempt to prevent the misuse of funding provided by the Global Fund, a system has been set in place for countries to apply for funding through submission of proposals and implementation plans. As a result of the impact of the Global Fund, seventeen and a half million people are being treated with antiretroviral therapy as of 2017.<ref>{{Cite news|url=https://www.cgdev.org/page/overview-global-fund-fight-aids-tuberculosis-and-malaria|title=Overview of the Global Fund to Fight AIDS, Tuberculosis and Malaria|work=Center For Global Development|access-date=2018-11-04|language=en}}</ref><ref>{{Cite news|url=https://www.kff.org/global-health-policy/fact-sheet/the-u-s-the-global-fund-to-fight-aids-tuberculosis-and-malaria/|title=The U.S. & The Global Fund to Fight AIDS, Tuberculosis and Malaria|date=2018-05-15|work=The Henry J. Kaiser Family Foundation|access-date=2018-11-04|language=en-US}}</ref><ref>{{Cite web|url=https://www.theglobalfund.org/en/hivaids/|title=HIV and AIDS|website=www.theglobalfund.org|access-date=2018-11-04}}</ref>

=== PEPFAR ===
In 2003, in an attempt to promote the importance of HIV research and funding, George W. Bush enacted the [[President's Emergency Plan for AIDS Relief|President's Emergency Plan for AIDS Relief (PEPFAR/Emergency Plan)]], committing the United States government to authorize $15 billion dollars to support HIV/AIDS, [[Tuberculosis|tuberculosis (TB)]]<nowiki/>and [[malaria]]<nowiki/>over a five year period in third-world countries.<ref>{{Cite news|url=https://www.cgdev.org/page/overview-president%E2%80%99s-emergency-plan-aids-relief-pepfar|title=Overview of the President’s Emergency Plan for AIDS Relief (PEPFAR)|work=Center For Global Development|access-date=2018-10-25|language=en}}</ref>With the improvement of ART treatment as a result of PEPFAR, the number of new infections has declined by 51-76% worldwide since the enactment of the Emergency Plan. In addition, the funding received from PEPFAR has allowed developing countries to treat millions, prevent millions of new infections and provide other care services to millions of already infected individuals.<ref>{{Cite news|url=https://www.kff.org/global-health-policy/fact-sheet/the-u-s-presidents-emergency-plan-for/|title=The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)|date=2017-12-19|work=The Henry J. Kaiser Family Foundation|access-date=2018-11-04|language=en-US}}</ref><ref>{{Cite web|url=https://www.hiv.gov/federal-response/pepfar-global-aids/pepfar|title=PEPFAR|website=HIV.gov|language=en|access-date=2018-11-04}}</ref><ref>{{Cite web|url=https://www.pepfar.gov/funding/results/index.htm|title=Latest PEPFAR Program Results|website=www.pepfar.gov|language=en-US|access-date=2018-11-04}}</ref>

=== Generic Drugs ===
Antiretroviral [[Generic drug|generic drugs]]<nowiki/>are medications that are identical to brand names drugs.<ref>{{Cite web|url=https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/genericdrugs/ucm167991.htm|title=Generic Drugs - Generic Drug Facts|last=Research|first=Center for Drug Evaluation and|website=www.fda.gov|language=en|access-date=2018-11-08}}</ref>Pharmaceutical companies in Brazil and India like [[Cipla]]<nowiki/>and Farmanguinhos have dedicated their efforts to reduce the prices of ART drugs. For example, Cipla has reduced prices of antiretroviral drugs for poor third-world countries to practically zero.<ref>{{Cite journal|last=Berwick|first=Donald|date=2002-01-26|title=“We all have AIDS”: case for reducing the cost of HIV drugs to zero|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1122133/|journal=BMJ : British Medical Journal|volume=324|issue=7331|pages=214–218|issn=0959-8138|pmc=PMC1122133|pmid=11809645}}</ref>Through their initatives in combination with pharmaceutical companies in Brazil, individuals in third-world countries are being provided access to antiretroviral treatment regimens that they could not afford before. Today, ART drug combinations cost $75 dollars in Africa.<ref>{{Cite journal|last=Martin|first=Erika G.|last2=Schackman|first2=Bruce R.|date=2018-01-25|title=Treating and Preventing HIV with Generic Drugs — Barriers in the United States|url=https://www.nejm.org/doi/full/10.1056/NEJMp1710914|journal=New England Journal of Medicine|language=en|volume=378|issue=4|pages=316–319|doi=10.1056/nejmp1710914|issn=0028-4793}}</ref><ref name=":92">{{Cite news|url=https://www.nytimes.com/2001/01/28/magazine/look-at-brazil.html|title=Look at Brazil|last=Rosenberg|first=Tina|access-date=2018-11-07|language=en}}</ref><ref name=":82">{{Cite news|url=https://www.nytimes.com/2018/09/18/opinion/pricing-hiv-drugs-america.html|title=Opinion {{!}} H.I.V. Drugs Cost $75 in Africa, $39,000 in the U.S. Does It Matter?|access-date=2018-11-07|language=en-US}}</ref><ref>{{Cite news|url=https://pulitzercenter.org/reporting/out-sight-out-mind-exploring-indias-hiv-epidemic|title=Out of Sight, Out of Mind: Exploring India's HIV Epidemic|date=2016-07-03|work=Pulitzer Center|access-date=2018-11-07|language=en}}</ref>

With the providing of generic drugs at such low costs in the developing world brings about turmoil regarding the current expensive prices of antiretroviral drugs in the United States. Antiretroviral drug regimens in the United States range in price from $10,000 to $40,000 as a result of pharmaceutical companies having control of price regulation. With this, the future of price reduction in the United States depends on pharmaceutical competition and negotiation to make antiretroviral drugs available to all low- and middle-income individuals despite where they may live in the world.<ref name=":82" /><ref>{{Cite news|url=http://www.aidsmap.com/HIV-treatment-is-costly-especially-for-the-sickest-patients/page/1516347/|title=HIV treatment is costly, especially for the sickest patients|access-date=2018-11-08}}</ref>

=== "Community-Based Care" ===
"Community-based care" refers to communities with high rates of HIV transmission and infected individuals taking the initiative to end the spread of AIDS within their own community. Community based care services include access to:

* HIV testing
* directly observed therapy with HAART (DOT-HAART)
** DOT-HAART refers to the administration and delivery of antiretroviral drugs by community members to ensure individuals adhere to drug regimens. Such community members observe the taking of medications to provide guidance and clarify any questions infected individuals may have.
* educational services regarding HIV transmission and prevention methods
* condoms and other barrier methods
* maternal-child transmission packages
* social services for families and orphaned children
* other services to ensure suppression of HIV transmission

The utilization of community-based care assists in the efforts in diminishing HIV transmission to reduce the number of new infections annually.<ref>{{Cite journal|last=Farmer|first=Paul|last2=Léandre|first2=Fernet|last3=Mukherjee|first3=Joia S|last4=Claude|first4=Marie Sidonise|last5=Nevil|first5=Patrice|last6=Smith-Fawzi|first6=Mary C|last7=Koenig|first7=Serena P|last8=Castro|first8=Arachu|last9=Becerra|first9=Mercedes C|date=August 2001|title=Community-based approaches to HIV treatment in resource-poor settings|url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(01)05550-7/fulltext|journal=The Lancet|language=English|volume=358|issue=9279|pages=404–409|doi=10.1016/S0140-6736(01)05550-7|issn=0140-6736|via=}}</ref><ref>{{Cite journal|last=Farmer|first=P.|last2=Léandre|first2=F.|last3=Mukherjee|first3=J.|last4=Gupta|first4=R.|last5=Tarter|first5=L.|last6=Kim|first6=J. Y.|date=2001|title=Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy).|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566712/|journal=Bulletin of the World Health Organization|volume=79|issue=12|pages=1145–1151|issn=0042-9686|pmc=PMC2566712|pmid=11799447}}</ref>

There have been studies of key populations in communities like Cape Town, South Africa that assert the benefits of community-based approaches, like adherence "clubs", where participants meet every two months for group counseling and the distribution of their ARV treatments.<ref>{{Cite journal|last=Grimsrud|first=Anna|last2=Lesosky|first2=Maia|last3=Kalombo|first3=Cathy|last4=Bekker|first4=Linda-Gail|last5=Myer|first5=Landon|title=Community-based Adherence Clubs for the management of stable antiretroviral therapy patients in Cape Town, South Africa|url=http://journals.lww.com/jaids/Fulltext/2016/01010/Implementation_and_Operational_Research__.18.aspx|journal=JAIDS Journal of Acquired Immune Deficiency Syndromes|language=en-US|volume=|pages=1|issn=1525-4135|via=}}</ref>

=== Cost-Effectiveness ===
In South Africa and India, a clinical trial was completed to determine the cost-effectiveness of administering antiretroviral drugs early to treat HIV. Sero-discordant couples were used in the study and each couple was provided either early or delayed antiretroviral treatment. Over a five-year period, researchers concluded that early ART was cost-saving in South Africa and cost-effective in India. Over a lifetime, early ART was determined to be very cost-effective in both countries. After the release of such results, other countries have concluded that it is cost-effective to utilize combination therapy resources especially when implementing them early into practice<ref>{{Cite journal|last=Walensky|first=Rochelle P.|last2=Ross|first2=Eric L.|last3=Kumarasamy|first3=Nagalingeswaran|last4=Wood|first4=Robin|last5=Noubary|first5=Farzad|last6=Paltiel|first6=A. David|last7=Nakamura|first7=Yoriko M.|last8=Godbole|first8=Sheela V.|last9=Panchia|first9=Ravindre|date=2013-10-31|title=Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples|url=https://www.nejm.org/doi/full/10.1056/nejmsa1214720|journal=New England Journal of Medicine|language=EN|volume=369|issue=18|pages=1715–1725|doi=10.1056/nejmsa1214720|issn=0028-4793|pmc=PMC3913536|pmid=24171517}}</ref><ref>{{Cite journal|last=Freedberg|first=Kenneth A.|last2=Losina|first2=Elena|last3=Weinstein|first3=Milton C.|last4=Paltiel|first4=A. David|last5=Cohen|first5=Calvin J.|last6=Seage|first6=George R.|last7=Craven|first7=Donald E.|last8=Zhang|first8=Hong|last9=Kimmel|first9=April D.|date=2001-03-15|title=The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease|url=https://www.nejm.org/doi/full/10.1056/NEJM200103153441108|journal=New England Journal of Medicine|language=EN|volume=344|issue=11|pages=824–831|doi=10.1056/nejm200103153441108|issn=0028-4793}}</ref><ref>{{Cite journal|last=Sanders|first=Gillian D.|last2=Bayoumi|first2=Ahmed M.|last3=Sundaram|first3=Vandana|last4=Bilir|first4=S. Pinar|last5=Neukermans|first5=Christopher P.|last6=Rydzak|first6=Chara E.|last7=Douglass|first7=Lena R.|last8=Lazzeroni|first8=Laura C.|last9=Holodniy|first9=Mark|date=2005-02-10|title=Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy|url=https://www.nejm.org/doi/full/10.1056/nejmsa042657|journal=New England Journal of Medicine|language=EN|volume=352|issue=6|pages=570–585|doi=10.1056/nejmsa042657|issn=0028-4793}}</ref>.

=== Prophylaxis ===

==== Pre-Exposure Prophylaxis ====
Antiretroviral chemoprophylaxis, or [[Pre-exposure prophylaxis|pre-exposure prophylaxis (PrEP)]], refers to the use of antiretroviral drugs prior to exposure of HIV as a precaution against transmission. PrEP is prescribed to individuals who are at high risk of contracting HIV and must be used daily to be effective. The most common regimen of PrEP is emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), two oral antiretroviral medications. PrEP reduces instances of HIV infection to nearly zero when utilized specifically as prescribed, which gives it the potential to have a population-wide scope.<ref>McCormack, S., et al (2014) ‘[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2900056-2/abstract Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial]’ The Lancet 387(10013):53-60</ref><ref>San Francisco Department of Public Health, Population Health Division (2015) '[http://www.sfdph.org/dph/files/reports/RptsHIVAIDS/HIV-EpidemiologyAnnualReport-2014.pdf HIV Epidemiology Annual Report 2014]'</ref> Around the world, PrEP has proven to diminish the chances of a HIV-negative individual from getting the disease and protects against the development and spreading of the virus within an individual's cells.<ref>{{Cite journal|last=Grant|first=Robert M.|last2=Lama|first2=Javier R.|last3=Anderson|first3=Peter L.|last4=McMahan|first4=Vanessa|last5=Liu|first5=Albert Y.|last6=Vargas|first6=Lorena|last7=Goicochea|first7=Pedro|last8=Casapía|first8=Martín|last9=Guanira-Carranza|first9=Juan Vicente|date=2010-12-30|title=Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men|url=https://www.nejm.org/doi/full/10.1056/NEJMoa1011205|journal=New England Journal of Medicine|language=EN|volume=363|issue=27|pages=2587–2599|doi=10.1056/nejmoa1011205|issn=0028-4793|pmc=PMC3079639|pmid=21091279}}</ref><ref>{{Cite web|url=https://www.cdc.gov/hiv/basics/prep.html|title=PrEP {{!}} HIV Basics {{!}} HIV/AIDS {{!}} CDC|date=2018-11-01|website=www.cdc.gov|language=en-us|access-date=2018-11-07}}</ref><ref>{{Cite journal|last=Paltiel|first=A. David|last2=Freedberg|first2=Kenneth A.|last3=Scott|first3=Callie A.|last4=Schackman|first4=Bruce R.|last5=Losina|first5=Elena|last6=Wang|first6=Bingxia|last7=Seage|first7=George R.|last8=Sloan|first8=Caroline E.|last9=Sax|first9=Paul E.|date=2009-03-15|title=HIV Pre-exposure Prophylaxis (PrEP) in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-effectiveness|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876329/|journal=Clinical infectious diseases : an official publication of the Infectious Diseases Society of America|volume=48|issue=6|pages=806–815|doi=10.1086/597095|issn=1058-4838|pmc=PMC2876329|pmid=19193111}}</ref><ref>{{Cite journal|last=Vissers|first=Debby C. J.|last2=Voeten|first2=Hélène A. C. M.|last3=Nagelkerke|first3=Nico J. D.|last4=Habbema|first4=J. Dik F.|last5=de Vlas|first5=Sake J.|date=2008-05-07|title=The Impact of Pre-Exposure Prophylaxis (PrEP) on HIV Epidemics in Africa and India: A Simulation Study|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2367053/|journal=PLoS ONE|volume=3|issue=5|doi=10.1371/journal.pone.0002077|issn=1932-6203|pmc=PMC2367053|pmid=18461185}}</ref> It is essential that PrEP is offered as part of a combination of preventative tactics, as it does not protect against other sexually transmitted diseases.<ref>UNAIDS (2015) ‘[http://www.unaids.org/sites/default/files/media_asset/UNAIDS_JC2764_en.pdf Oral pre-exposure prophylaxis: putting a new choice in context]’</ref>

One form of PrEP is a microbicide treatment, or "topical PrEP". Microbicides are ARVs that come in the form of gels or creams that are put on the vagina to prevent HIV infection. In the [[CAPRISA 004]] trial in South Africa, there were found to generally be 39% fewer infections among women who used microbicide gel, however those results have not been recreated.<ref>Abdool Karim, S. et al (2010) ‘[http://science.sciencemag.org/content/329/5996/1168.abstract Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women]’ Science 329(5996):1168-1174</ref> In 2015, WHO defined a new precedent for offering PrEP to at-risk HIV-negative individuals, which expanded the definition of a high risk individual to include people who have an HIV-positive partner, those who do not have access to condoms, and those who are frequently having unprotected sex. Prior to 2015, PrEP was only initiated for key populations like sex workers, injection drug users, and men who have sex with men.<ref>World Health Organization (WHO) (2015) '[http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/ Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV]'</ref><ref>World Health Organization (WHO) (2015) '[http://apps.who.int/iris/bitstream/10665/197906/1/WHO_HIV_2015.48_eng.pdf?ua=1 Policy brief: WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP)]'</ref>

==== Post-Exposure Prophylaxis ====
[[Post-exposure prophylaxis|Post-exposure prophylaxis (PEP)]] refers to the temporary use of antiretroviral drugs when an HIV-negative individual has been potentially exposed to HIV. PEP must be taken 36-72 hours after exposure to prevent viral replication and acquisition of the virus. The medication must be taken daily for 28 days to ensure the elimination of HIV. One of the most common PEP regimens is [[Emtricitabine/tenofovir|Truvada]]. When determining whether to prescribe PEP, doctors analyze the HIV status and viral load of the infected partner in addition to the type of HIV exposure to draw conclusions regarding the amount of risk the non-infected partner faces regarding the development of the infection. It has been concluded that individuals who experience blood or mucosal exposure to an HIV-infected individual who has a high viral load experience the greatest risk to HIV transmission.

PEP has mostly been used by those in healthcare professions—an example being the use of PEP by nurses who accidentally become exposed to HIV by infected bodily fluids—yet PEP has been used more recently as emergency prevention for someone who may have been exposed to HIV in a one-time event, such as unprotected sex or sharing needles.<ref>Henderson, D.K. and Gerberding, J.L. (1989) '[http://www.ncbi.nlm.nih.gov/pubmed/2760486 Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis]' The Journal of Infectious Diseases 160(2):321-327</ref><ref>Smith, D.K. et al (2005) [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5402a1.htm 'Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States'] Morbidity and Mortality Weekly Report 54(2):1-20</ref> There are currently no clinical trials to analyze the efficacy of PEP due to ethical reasons such as the ethics surrounding withholding treatment or PEP from individuals who have potentially been infected with the virus.

PEP requires further testing and trial before its efficacy is universally accepted, however one experiment in the mid 90s revealed that zidovudine would prevent the transmission of HIV to exposed healthcare workers in 81% of cases.<ref>Cardo, D.M. et al (1997) 'A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure' The New England Journal of Medicine 337:1485-1490</ref> Zidovudine has however since been phased out and replaced by tenofovir in three-drug combinations.<ref>British HIV Association (BHIVA) (2014, 10 September) '[http://www.bhiva.org/change-to-the-recommended-regimen-for-PEP.aspx Change to the recommended regimen for post-exposure prophylaxis (PEP)]'</ref> PEP has the potential to prevent the spreading of HIV to individuals who are not on PrEP and have been exposed to the virus.<ref>{{Cite journal|last=Sultan|first=Binta|last2=Benn|first2=Paul|last3=Waters|first3=Laura|date=2014-10-24|title=Current perspectives in HIV post-exposure prophylaxis|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216036/|journal=HIV/AIDS (Auckland, N.Z.)|volume=6|pages=147–158|doi=10.2147/HIV.S46585|issn=1179-1373|pmc=PMC4216036|pmid=25368534}}</ref><ref>{{Cite web|url=https://www.cdc.gov/hiv/basics/pep.html|title=PEP {{!}} HIV Basics {{!}} HIV/AIDS {{!}} CDC|date=2018-07-23|website=www.cdc.gov|language=en-us|access-date=2018-11-07}}</ref><ref>{{Cite news|url=https://journals.lww.com/aidsonline/Fulltext/2002/02150/Post_exposure_prophylaxis_after_non_occupational.11.aspx|title=Post-exposure prophylaxis after non-occupational HIV... : AIDS|work=LWW|access-date=2018-11-07|language=en-US}}</ref>

=== Single-tablet Regimens ===
When doctors prescribe antiretroviral drugs to patients, the initial prescriptions consist of drug regimens that contain multiple pills of different classes that must be taken daily. Although triple therapy is most commonly used, there are single-tablet regimens (STRs) that exist to treat AIDS. STRs are created through combining three antiretroviral drugs into one pill. Single-tablet regimens are only available at specific clinics around the world—meaning there is limited access to these regimens—and are only prescribed if a doctor feels a patient will struggle with the treatment schedule of antiretroviral therapy. The implementation of STRs worldwide could serve as a replacement for the triple-drug antiretroviral therapy and allow patients to have a less strict ART schedule to abide by.<ref>{{Cite news|url=http://www.aidsmap.com/Single-tablet-regimens/page/2291689/|title=Anti-HIV drugs - Single-tablet regimens|access-date=2018-11-03}}</ref><ref>{{Cite journal|last=Astuti|first=Noemi|last2=Maggiolo|first2=Franco|date=June 2014|title=Single-Tablet Regimens in HIV Therapy|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108118/|journal=Infectious Diseases and Therapy|volume=3|issue=1|pages=1–17|doi=10.1007/s40121-014-0024-z|issn=2193-8229|pmc=PMC4108118|pmid=25134808|via=}}</ref><ref>{{Cite journal|last=Truong|first=William R.|last2=Schafer|first2=Jason J.|last3=Short|first3=William R.|date=January 2015|title=Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296592/|journal=Pharmacy and Therapeutics|volume=40|issue=1|pages=44–55|issn=1052-1372|pmc=PMC4296592|pmid=25628507|via=}}</ref>

=== Injectable HIV-1 Treatment ===
The greatest struggle faced by HIV-positive individuals is maintaining compliance of taking the ART pills every day. The lack of compliance can lead to drug failure or drug resistance. In July of 2017, ''The Lancet''released an article revealing the results of a study conducted involving an injectable HIV-1 treatment to serve as a future replacement for the three-drug oral combination therapy. This new treatment would consist of two drugs: [[cabotegravir]]<nowiki/>and [[rilpivirine]]<nowiki/>and injections would occur every four to eight weeks for each patient. Thus far, the treatment has passed [[Phases of clinical research|Phase II]]<nowiki/>of the clinical trial and has been proven to be just as effective as the oral regimen.<ref>{{Cite journal|last=Margolis|first=David A|last2=Gonzalez-Garcia|first2=Juan|last3=Stellbrink|first3=Hans-Jürgen|last4=Eron|first4=Joseph J|last5=Yazdanpanah|first5=Yazdan|last6=Podzamczer|first6=Daniel|last7=Lutz|first7=Thomas|last8=Angel|first8=Jonathan B|last9=Richmond|first9=Gary J|date=September 2017|title=Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial|url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31917-7/fulltext?elsca1=tlpr%5Bthelancet.com%5D|journal=The Lancet|language=English|volume=390|issue=10101|pages=1499–1510|doi=10.1016/S0140-6736(17)31917-7|issn=0140-6736|via=}}</ref><ref>{{Cite news|url=http://www.sciencemag.org/news/2018/08/ditching-daily-pills-monthly-shots-could-transform-hiv-treatment-and-prevention|title=Swapping daily pills for monthly shots could transform HIV treatment and prevention|date=2018-08-22|work=Science {{!}} AAAS|access-date=2018-11-07|language=en}}</ref><ref>{{Cite journal|last=Klooster|first=Gerben van ′t|last2=Hoeben|first2=Eva|last3=Borghys|first3=Herman|last4=Looszova|first4=Adriana|last5=Bouche|first5=Marie-Paule|last6=Velsen|first6=Frans van|last7=Baert|first7=Lieven|date=2010-05-01|title=Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation|url=https://aac.asm.org/content/54/5/2042|journal=Antimicrobial Agents and Chemotherapy|language=en|volume=54|issue=5|pages=2042–2050|doi=10.1128/AAC.01529-09|issn=0066-4804|pmid=20160045}}</ref><ref>{{Cite journal|last=Spreen|first=William R.|last2=Margolis|first2=David A.|last3=Pottage|first3=John C.|date=November 2013|title=Long-acting injectable antiretrovirals for HIV treatment and prevention|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815009/|journal=Current Opinion in HIV and AIDS|volume=8|issue=6|pages=565–571|doi=10.1097/COH.0000000000000002|issn=1746-630X|pmc=PMC3815009|pmid=24100877|via=}}</ref>

In August of 2018, ViiV Healthcare, a collaboration between GlaxoSmithKline and Pfizer revealed the findings of a study that found that receiving monthly injections of two long-acting ARVs over a course of 48 weeks is just as effective as taking daily pills. However, logistical questions still remain about cost, the effect of missed shots, and side effects of taking monthly injections. The study, which is called Antiretroviral Therapy as Long-Acting Suppression (ATLAS) is experimenting with the drugs cabotegravir--made by ViiV--and rilpivrine, which is a licensed drug from Janssen Sciences Ireland UC. ATLAS has a scope of 618 HIV-positive individuals from 13 countries, all of which had reached undetectability. Half of the participants continued with daily pills, while the others switched to receiving an injection each month. Viral suppression was the same in both groups. The results of the ATLAS study may also impact those who are not yet infected and are participating in PrEP, yet are reluctant to take daily pills. Other studies are underway which are testing viral suppression in HIV-positive people who have never taken antiretrovirals, and whether the injectables are still effective when only taken once every 8 weeks. With the introduction of long-acting drugs come questions on the optimal dose and timing, and how the virus may mutate to become resistant to the new form of treatment.<ref>{{Cite news|url=https://www.sciencemag.org/news/2018/08/ditching-daily-pills-monthly-shots-could-transform-hiv-treatment-and-prevention|title=Swapping daily pills for monthly shots could transform HIV treatment and prevention|date=2018-08-22|work=Science {{!}} AAAS|access-date=2018-10-30|language=en}}</ref>

=== Microbicides ===
In an attempt to prevent the spread of HIV to an HIV-negative individual, HIV-specific microbicides can be utilized to interrupt the viral life cycle. As a result of the interruption by the microbicides, the viral DNA transcribed from HIV RNA cannot be integrated into a host cell's genome by the enzyme [[integrase]]. The inability of HIV to infect host cells allows an individual to be safe from contracting the infection. In relation to the viral life cycle, microbicides can be used to disrupt the absorption of the virus into the body, the fusion of the viral and host cell's membranes, transcription of viral DNA and the integration of viral DNA into the genome of the host cell. For example, to prevent the fusion of the viral and host cell's membrane, monoclonal antibodies, which are virus entry inhibitors, can be placed into the human body to prevent the interaction between the CD4 receptors and the viral HIV envelope protein [[Envelope glycoprotein GP120|gp120]]. In addition, post-entry inhibitors can be placed into the body to block the virus once it has entered the host cell. To be utilized, post-entry inhibitors must be released when viral reverse transcriptase or viral integrase are inhibited and replicated rapidly to combat the virus.<ref>{{Cite journal|last=Balzarini|first=Jan|last2=Van Damme|first2=Lut|date=March 2007|title=Microbicide drug candidates to prevent HIV infection|url=https://www.thelancet.com/action/showPdf?pii=S0140-6736(07)60202-5|journal=The Lancet|language=English|volume=369|issue=9563|pages=787–797|doi=10.1016/S0140-6736(07)60202-5|issn=0140-6736|via=}}</ref><ref name=":4">{{Cite journal|date=2010-03-18|title=Nanotechnology-based systems for the treatment and prevention of HIV/AIDS|url=https://www.sciencedirect.com/science/article/pii/S0169409X09003585|journal=Advanced Drug Delivery Reviews|language=en|volume=62|issue=4-5|pages=458–477|doi=10.1016/j.addr.2009.11.017|issn=0169-409X}}</ref><ref>{{Cite web|url=https://www.hiv.gov/hiv-basics/hiv-prevention/potential-future-options/microbicides|title=Microbicides|website=HIV.gov|language=en|access-date=2018-11-07}}</ref><ref>{{Cite journal|last=Naswa|first=Smriti|last2=Marfatia|first2=Y. S.|last3=Prasad|first3=T. L. N.|date=2012|title=Microbicides and HIV: A Review and an update|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505301/|journal=Indian Journal of Sexually Transmitted Diseases and AIDS|volume=33|issue=2|pages=81–90|doi=10.4103/2589-0557.102098|issn=2589-0557|pmc=PMC3505301|pmid=23188931}}</ref><ref name=":10">{{Cite journal|last=Shattock|first=Robin J.|last2=Rosenberg|first2=Zeda|date=February 2012|title=Microbicides: Topical Prevention against HIV|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281595/|journal=Cold Spring Harbor Perspectives in Medicine|volume=2|issue=2|pages=|doi=10.1101/cshperspect.a007385|issn=2157-1422|pmc=PMC3281595|pmid=22355798|via=}}</ref>

In addition, prior to intercourse, a topical microbicide product can be inserted in the vagina or rectum to prevent the spread of HIV/AIDs between partners.<ref name=":4" /><ref name=":10" />


==References==
==References==

Revision as of 00:39, 10 November 2018

Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of the transmission of an infection from an infected individual to others. The term is primarily used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to lower the risk of new HIV infection transmissions. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans.[1] Other names for ART include highly active antiretroviral therapy (HAART), combination antiretroviral therapy (cART), triple therapy and triple drug cocktail.[2]

When taken correctly, ARVs are able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability.[3] Undetectability ensures that infection does not necessarily have an effect on a person's general health, and that there is no longer a risk of passing along HIV to others. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.

Although evidence through clinical trials like HTPN 052 reveal positive results in regards to the implementation of antiretroviral drugs as preventative measures against HIV transmission, challenges such as overall cost[4] and drug resistance[5] prevent such initiatives to be put into action. As a result, efforts to find solutions to such challenges and risks have been the main focus in research efforts, the goal being to reach a point in time where HIV treatment as prevention becomes a main part of public health initiatives to combat HIV/AIDS.[6]

TasP's legitimacy has influenced the World Health Organization's (WHO) standards for "test and treat" strategies, which push to alert as many people as possible of their HIV status through testing, and start people infected with HIV on ARVs, no matter their viral load or CD4 count.[7] The diminished rate of new HIV infections brought about by these strategies are marked progress towards UNAIDS' 90-90-90 target to eliminate HIV/AIDS as a public health crisis by 2030.[8] However, key populations in countries in Africa, Asia, and the Middle East still have lower access to treatment and the benefits it brings, as a result of the stigma that surrounds HIV.[9]

Today, treatment as prevention has not been implemented permanently into practice.[6]

HIV Prevention Trials Network Clinical Trial 052

The HIV Prevention Trials Network conducted a clinical trial, HPTN 052, that analyzed the effectiveness of antiretroviral drugs on the HIV-1 virus. 1,783 HIV sero-discordant couples, or couples that consist of an HIV-positive individual and an HIV-negative partner, from nine different countries were a part of the study, 97% of the couples being heterosexual. In August of 2011, the HIV Prevention Trials Network concluded that the likelihood of transmission between the couples who were provided early antiretroviral therapy reduced by 96%. When the trial completed, the overall reduction percentage of HIV-1 transmission between couples who were treated early with ART or received the delay-ART treatment was 93%.[10][11][12][13] The study's purpose was to reveal that HIV-1 viral transmission can be prevented through treatment, leading many regions to incorporate a treatment as prevention plan into their public health policy for responding to HIV.[11][12][14]

Implementation

Treatment as prevention has been used as a form of controlling the spread of HIV since the mid-1990s, initially in the context of preventing the transmission of the virus from mothers to their children. Research in 1994 revealed how the drug zidovudine can reduce vertical transmission.[15] The testing and treatment of HIV-positive mothers during pregnancy, childbirth, and breastfeeding has since led to the reduction of the risk of transmission by up to 95%.[16] A program for offering ARVs for life to any HIV-positive pregnant person called "Option B+" served as a precursor to the "test and treat" strategy that is now being rolled out in various countries.[17] Assessments of the Option B+ program are able to aid in the improvement and further establishment of "test and treat".[17]

From 2013 to 2015, the global amount of people receiving ARV treatment rose by a third, and now is at 18.2 million people.[18] This is a result of increased use of "test and treat". In 2015, about one fourth of the 148 countries informed about national treatment plans had initiated the WHO's "test and treat" approaches, and 44 more countries pledged to implement them by the end of 2016.[19] The five-year HPTN 071 "PopART" study is currently examining the efficacy of TasP in 21 communities throughout South Africa and Zambia.[20] PopART is focused on the advantages and downfalls of providing free voluntary HIV testing in combination with instant treatment for those who test positive.[21] This study has a scope of about 1 million residents, making it the largest executed test of "test and treat".[22]

Challenges and Risks Associated with Treatment as Prevention

While TasP has a huge potential to prevent the further spread of HIV worldwide, the most vulnerable populations are not seeing these benefits as a result of a social and political climate that is deterrent to seeking testing and treatment, in addition to making it difficult to stick with the ARV regimen.[23] With this, antiretroviral therapy should be implemented within every country's public health policy, yet challenges and risks are faced when such implementation is put into action.

Overall Cost of Treatment

For many countries, especially low- and middle-income countries, the overall cost of treatment in the 1990s and early 2000s was too expensive for infected patients to afford it. In addition, individuals with low incomes in United States struggle to pay high prices set by pharmaceutical companies for antiretroviral drugs. As a result, it is currently implausible for a global treatment system or policy to be put into place since no universal HIV/AIDS test and medication regimen exists because of technology and wealth disparities worldwide.[24][25][26][27]

Side Effects Caused by ART

Antiretroviral drugs can also cause patients to experience various side effects including becoming nauseated or suffering from gastrointestinal pains and issues, as a results of medications at times being too toxic for a specific individual. In addition, in low and middle income countries (LMICs), an increase in the number of side effects expressed in a country leads to the underdeveloped health care systems of said country having to use their limited funds to account for service delivery costs of medications to counter the newly inflicted problems among infected individuals.[28][29][30][31][32][33]

HIV-1 Drug Resistance

HIV drug resistance has also come to the forefront of worries in regards to how effective TasP can be against the spread of the virus. The widespread global use of ARVs is feared to lead to an increase in drug resistance as a result of interrupted treatment and a lack of adherence.[34]

Developed countries, when first discussing the implementation of ART in the developing world, believed that the allowance of third-world countries to have early access to antiretroviral drugs would potentially lead to the development of drug resistance. Recently, such resistance has developed in third-world countries as a result of medication combinations failing to diminish the viral load of HIV-1 in infected individuals, the lack of existence of virological testing to discover such failures in patients in these regions of the world and the lack of different variants of medication regimens to suppress the evolution of the infection.[35][36][37][38]

In the case of resistance to the first-line of combination medications for the HIV-1 virus, mutations occurred within genes of HIV-1 viral RNA that enters T-cells within the human body. Mutations are the result of reverse transcriptase, the enzyme that is responsible for reverse-transcribing the viral RNA into viral DNA, having a high error rate when copying the viral RNA. The mutations occur within the nucleotide bases of the new viral DNA.[39]

After the mutated viral DNA is implemented into the host cell's DNA, the DNA is translated to produce viral proteins that will assist in the infecting of other surrounding cells. When translated, the mutations lead to different amino acids formulating the viral proteins. The primary proteins that are focused upon in relation to HIV-1 are the viral protease and reverse transcriptase because these enzymes are the ones that are inhibited by antiretroviral medications.[39]

Overall, the transmitted drug resistance (TDR) among resource-limited setting (RLS) adults in regions such as Africa, Asia and Brazil has increased, the calculated rate of TDR being 6.6% as of 2015. In addition, studies that were conducted within these regions revealed a correlation between the length of time ART was implemented as a method of treatment and the likelihood of the establishment of TDR. The studies concluded that the likelihood of TDR in LMICs is 1.7 times greater if ART is implemented for equal to or more than five years.[35]

HIV resistance is largely an issue in the global south, where the health infrastructure is not conducive to support those participating in the life-long and intensive treatment of HIV/AIDS.[40]

Necessity for Adherence

Antiretroviral therapy requires HIV-positive individuals to abide by strict adherence and thrives when countries have the necessary HIV services available for infected individuals to access. Management of HIV/AIDS includes services such as HIV testing and diagnosing, consistent HIV care and treatment, education lessons regarding how to use ART effectively and distribution methods to ensure individuals receive their medications. In LMICs, the lack of HIV testing, which, in turn, create a lack of HIV diagnosing limits the opportunity for the initiation of treatment as a preventative method because most infected individuals are unaware of their current condition.[41][42][43][44][45][46]

For example, a study in 2011 revealed that in the United States, 15 years after the implementation of highly active antiretroviral therapy (HAART), and 4 years after the initial use of combination prevention, only 19% of the 1.1 million HIV-positive people in the country had reduced their viral load to reach undetectability.[47]

Additionally, the window of time between initial infection and first getting tested is too large in some areas, meaning that people with HIV have a higher chance of passing along the virus while their viral load is high, even if they do eventually seek TasP.[23] Even once TasP is initiated, its success depends on adherence to the treatment. If interrupted, the more sensitive strains of HIV become suppressed, while leaving the more resistant and harder to treat strains to become more dominant.[48] Even in areas where access to treatment is fairly eased, adherence has emerged as an issue.

Short-Term and Long-Term Solutions

Global Fund

In 2002, The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund)was a financial initiative developed to raise and provide funding to the developing world in an attempt to enhance their care and treatment programs for individuals who are living with HIV/AIDS, TB and malaria. For the international organization to be successful, developed countries must work in conjunction with third-world countries, private organizations, civil society and afflicted communities to ease the impact of the epidemics. In an attempt to prevent the misuse of funding provided by the Global Fund, a system has been set in place for countries to apply for funding through submission of proposals and implementation plans. As a result of the impact of the Global Fund, seventeen and a half million people are being treated with antiretroviral therapy as of 2017.[49][50][51]

PEPFAR

In 2003, in an attempt to promote the importance of HIV research and funding, George W. Bush enacted the President's Emergency Plan for AIDS Relief (PEPFAR/Emergency Plan), committing the United States government to authorize $15 billion dollars to support HIV/AIDS, tuberculosis (TB)and malariaover a five year period in third-world countries.[52]With the improvement of ART treatment as a result of PEPFAR, the number of new infections has declined by 51-76% worldwide since the enactment of the Emergency Plan. In addition, the funding received from PEPFAR has allowed developing countries to treat millions, prevent millions of new infections and provide other care services to millions of already infected individuals.[53][54][55]

Generic Drugs

Antiretroviral generic drugsare medications that are identical to brand names drugs.[56]Pharmaceutical companies in Brazil and India like Ciplaand Farmanguinhos have dedicated their efforts to reduce the prices of ART drugs. For example, Cipla has reduced prices of antiretroviral drugs for poor third-world countries to practically zero.[57]Through their initatives in combination with pharmaceutical companies in Brazil, individuals in third-world countries are being provided access to antiretroviral treatment regimens that they could not afford before. Today, ART drug combinations cost $75 dollars in Africa.[58][59][60][61]

With the providing of generic drugs at such low costs in the developing world brings about turmoil regarding the current expensive prices of antiretroviral drugs in the United States. Antiretroviral drug regimens in the United States range in price from $10,000 to $40,000 as a result of pharmaceutical companies having control of price regulation. With this, the future of price reduction in the United States depends on pharmaceutical competition and negotiation to make antiretroviral drugs available to all low- and middle-income individuals despite where they may live in the world.[60][62]

"Community-Based Care"

"Community-based care" refers to communities with high rates of HIV transmission and infected individuals taking the initiative to end the spread of AIDS within their own community. Community based care services include access to:

  • HIV testing
  • directly observed therapy with HAART (DOT-HAART)
    • DOT-HAART refers to the administration and delivery of antiretroviral drugs by community members to ensure individuals adhere to drug regimens. Such community members observe the taking of medications to provide guidance and clarify any questions infected individuals may have.
  • educational services regarding HIV transmission and prevention methods
  • condoms and other barrier methods
  • maternal-child transmission packages
  • social services for families and orphaned children
  • other services to ensure suppression of HIV transmission

The utilization of community-based care assists in the efforts in diminishing HIV transmission to reduce the number of new infections annually.[63][64]

There have been studies of key populations in communities like Cape Town, South Africa that assert the benefits of community-based approaches, like adherence "clubs", where participants meet every two months for group counseling and the distribution of their ARV treatments.[65]

Cost-Effectiveness

In South Africa and India, a clinical trial was completed to determine the cost-effectiveness of administering antiretroviral drugs early to treat HIV. Sero-discordant couples were used in the study and each couple was provided either early or delayed antiretroviral treatment. Over a five-year period, researchers concluded that early ART was cost-saving in South Africa and cost-effective in India. Over a lifetime, early ART was determined to be very cost-effective in both countries. After the release of such results, other countries have concluded that it is cost-effective to utilize combination therapy resources especially when implementing them early into practice[66][67][68].

Prophylaxis

Pre-Exposure Prophylaxis

Antiretroviral chemoprophylaxis, or pre-exposure prophylaxis (PrEP), refers to the use of antiretroviral drugs prior to exposure of HIV as a precaution against transmission. PrEP is prescribed to individuals who are at high risk of contracting HIV and must be used daily to be effective. The most common regimen of PrEP is emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), two oral antiretroviral medications. PrEP reduces instances of HIV infection to nearly zero when utilized specifically as prescribed, which gives it the potential to have a population-wide scope.[69][70] Around the world, PrEP has proven to diminish the chances of a HIV-negative individual from getting the disease and protects against the development and spreading of the virus within an individual's cells.[71][72][73][74] It is essential that PrEP is offered as part of a combination of preventative tactics, as it does not protect against other sexually transmitted diseases.[75]

One form of PrEP is a microbicide treatment, or "topical PrEP". Microbicides are ARVs that come in the form of gels or creams that are put on the vagina to prevent HIV infection. In the CAPRISA 004 trial in South Africa, there were found to generally be 39% fewer infections among women who used microbicide gel, however those results have not been recreated.[76] In 2015, WHO defined a new precedent for offering PrEP to at-risk HIV-negative individuals, which expanded the definition of a high risk individual to include people who have an HIV-positive partner, those who do not have access to condoms, and those who are frequently having unprotected sex. Prior to 2015, PrEP was only initiated for key populations like sex workers, injection drug users, and men who have sex with men.[77][78]

Post-Exposure Prophylaxis

Post-exposure prophylaxis (PEP) refers to the temporary use of antiretroviral drugs when an HIV-negative individual has been potentially exposed to HIV. PEP must be taken 36-72 hours after exposure to prevent viral replication and acquisition of the virus. The medication must be taken daily for 28 days to ensure the elimination of HIV. One of the most common PEP regimens is Truvada. When determining whether to prescribe PEP, doctors analyze the HIV status and viral load of the infected partner in addition to the type of HIV exposure to draw conclusions regarding the amount of risk the non-infected partner faces regarding the development of the infection. It has been concluded that individuals who experience blood or mucosal exposure to an HIV-infected individual who has a high viral load experience the greatest risk to HIV transmission.

PEP has mostly been used by those in healthcare professions—an example being the use of PEP by nurses who accidentally become exposed to HIV by infected bodily fluids—yet PEP has been used more recently as emergency prevention for someone who may have been exposed to HIV in a one-time event, such as unprotected sex or sharing needles.[79][80] There are currently no clinical trials to analyze the efficacy of PEP due to ethical reasons such as the ethics surrounding withholding treatment or PEP from individuals who have potentially been infected with the virus.

PEP requires further testing and trial before its efficacy is universally accepted, however one experiment in the mid 90s revealed that zidovudine would prevent the transmission of HIV to exposed healthcare workers in 81% of cases.[81] Zidovudine has however since been phased out and replaced by tenofovir in three-drug combinations.[82] PEP has the potential to prevent the spreading of HIV to individuals who are not on PrEP and have been exposed to the virus.[83][84][85]

Single-tablet Regimens

When doctors prescribe antiretroviral drugs to patients, the initial prescriptions consist of drug regimens that contain multiple pills of different classes that must be taken daily. Although triple therapy is most commonly used, there are single-tablet regimens (STRs) that exist to treat AIDS. STRs are created through combining three antiretroviral drugs into one pill. Single-tablet regimens are only available at specific clinics around the world—meaning there is limited access to these regimens—and are only prescribed if a doctor feels a patient will struggle with the treatment schedule of antiretroviral therapy. The implementation of STRs worldwide could serve as a replacement for the triple-drug antiretroviral therapy and allow patients to have a less strict ART schedule to abide by.[86][87][88]

Injectable HIV-1 Treatment

The greatest struggle faced by HIV-positive individuals is maintaining compliance of taking the ART pills every day. The lack of compliance can lead to drug failure or drug resistance. In July of 2017, The Lancetreleased an article revealing the results of a study conducted involving an injectable HIV-1 treatment to serve as a future replacement for the three-drug oral combination therapy. This new treatment would consist of two drugs: cabotegravirand rilpivirineand injections would occur every four to eight weeks for each patient. Thus far, the treatment has passed Phase IIof the clinical trial and has been proven to be just as effective as the oral regimen.[89][90][91][92]

In August of 2018, ViiV Healthcare, a collaboration between GlaxoSmithKline and Pfizer revealed the findings of a study that found that receiving monthly injections of two long-acting ARVs over a course of 48 weeks is just as effective as taking daily pills. However, logistical questions still remain about cost, the effect of missed shots, and side effects of taking monthly injections. The study, which is called Antiretroviral Therapy as Long-Acting Suppression (ATLAS) is experimenting with the drugs cabotegravir--made by ViiV--and rilpivrine, which is a licensed drug from Janssen Sciences Ireland UC. ATLAS has a scope of 618 HIV-positive individuals from 13 countries, all of which had reached undetectability. Half of the participants continued with daily pills, while the others switched to receiving an injection each month. Viral suppression was the same in both groups. The results of the ATLAS study may also impact those who are not yet infected and are participating in PrEP, yet are reluctant to take daily pills. Other studies are underway which are testing viral suppression in HIV-positive people who have never taken antiretrovirals, and whether the injectables are still effective when only taken once every 8 weeks. With the introduction of long-acting drugs come questions on the optimal dose and timing, and how the virus may mutate to become resistant to the new form of treatment.[93]

Microbicides

In an attempt to prevent the spread of HIV to an HIV-negative individual, HIV-specific microbicides can be utilized to interrupt the viral life cycle. As a result of the interruption by the microbicides, the viral DNA transcribed from HIV RNA cannot be integrated into a host cell's genome by the enzyme integrase. The inability of HIV to infect host cells allows an individual to be safe from contracting the infection. In relation to the viral life cycle, microbicides can be used to disrupt the absorption of the virus into the body, the fusion of the viral and host cell's membranes, transcription of viral DNA and the integration of viral DNA into the genome of the host cell. For example, to prevent the fusion of the viral and host cell's membrane, monoclonal antibodies, which are virus entry inhibitors, can be placed into the human body to prevent the interaction between the CD4 receptors and the viral HIV envelope protein gp120. In addition, post-entry inhibitors can be placed into the body to block the virus once it has entered the host cell. To be utilized, post-entry inhibitors must be released when viral reverse transcriptase or viral integrase are inhibited and replicated rapidly to combat the virus.[94][95][96][97][98]

In addition, prior to intercourse, a topical microbicide product can be inserted in the vagina or rectum to prevent the spread of HIV/AIDs between partners.[95][98]

References

  1. ^ "Treatment as prevention (TasP) for HIV". AVERT. 2015-07-20. Retrieved 2018-10-29.
  2. ^ "What Is HAART (Highly Active Antiretroviral Therapy)?". Verywell Health. Retrieved 2018-10-29.
  3. ^ World Health Organization (WHO) (2012) 'Antiretroviral treatment as prevention (TASP) of HIV and TB'[pdf]
  4. ^ "Antiretroviral Therapy Is the Biggest Expense in HIV Care". POZ. 2010-09-23. Retrieved 2018-11-07.
  5. ^ Stadeli, Kathryn M; Richman, Douglas D (2012). "Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review". Antiviral Therapy. 18 (1): 115–123. doi:10.3851/IMP2437. ISSN 1359-6535.
  6. ^ a b Hull, Mark; Lange, Joep; Montaner, Julio S.G. (December 2014). "Treatment as Prevention–Where Next?". Current HIV/AIDS reports. 11 (4): 496–504. doi:10.1007/s11904-014-0237-5. ISSN 1548-3568. PMC 4268430. PMID 25384357.{{cite journal}}: CS1 maint: PMC format (link)
  7. ^ World Health Organization (WHO) (2015) 'Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV'
  8. ^ UNAIDS (2014/2017) ‘90-90-90: An ambitious treatment target to help end the AIDS epidemic’[pdf]
  9. ^ UNAIDS (2016) 'Prevention Gap Report'[pdf]
  10. ^ "The HIV Prevention Trials Network | Prevention Now". www.hptn.org. Retrieved 2018-10-23.
  11. ^ a b Cohen, Myron S.; Chen, Ying Q.; McCauley, Marybeth; Gamble, Theresa; Hosseinipour, Mina C.; Kumarasamy, Nagalingeswaran; Hakim, James G.; Kumwenda, Johnstone; Grinsztejn, Beatriz (2011-08-11). "Prevention of HIV-1 Infection with Early Antiretroviral Therapy". New England Journal of Medicine. 365 (6): 493–505. doi:10.1056/nejmoa1105243. ISSN 0028-4793. PMC 3200068. PMID 21767103.{{cite journal}}: CS1 maint: PMC format (link)
  12. ^ a b Cohen, Myron S.; Chen, Ying Q.; McCauley, Marybeth; Gamble, Theresa; Hosseinipour, Mina C.; Kumarasamy, Nagalingeswaran; Hakim, James G.; Kumwenda, Johnstone; Grinsztejn, Beatriz (September 2016). "Antiretroviral Therapy for the Prevention of HIV-1 Transmission". New England Journal of Medicine. 375 (9): 830–839. doi:10.1056/nejmoa1600693. ISSN 0028-4793. PMC 5049503. PMID 27424812.{{cite journal}}: CS1 maint: PMC format (link)
  13. ^ "Publication of HPTN 052 Final Results: HIV Treatment Offers Durable Prevention of HIV Transmission in Sero-discordant Couples | The HIV Prevention Trials Network". www.hptn.org. Retrieved 2018-11-07.
  14. ^ Cohen, Jon (2011-12-23). "HIV Treatment as Prevention". Science. 334 (6063): 1628–1628. doi:10.1126/science.334.6063.1628. ISSN 0036-8075. PMID 22194547.
  15. ^ Connor, E.M. et al (1994) 'Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment' The New England Journal of Medicine 331:1173-1180
  16. ^ World Health Organization (WHO) 'Mother-to-child transmission of HIV' [accessed 23 May 2016]
  17. ^ a b Kalua, T. et al (2017) ‘Lessons Learned From Option B+ in the Evolution Toward “Test and Start” From Malawi, Cameroon, and the United Republic of Tanzania’ Journal of Acquired Immune Deficiency Syndromes
  18. ^ UNAIDS (2016) 'Get on the Fast-Track' [pdf]
  19. ^ UNAIDS (2016) 'Prevention Gap Report'[pdf]
  20. ^ Cori, A. et al (2014) 'HPTN 071 (PopART): A Cluster-Randomized Trial of the Population Impact of an HIV Combination Prevention Intervention Including Universal Testing and Treatment: Mathematical Model' PLOS One 9(1):e84511
  21. ^ London School of Hygiene & Tropical Medicine 'HPTN 071 (PopART)'
  22. ^ HPTN (2017) ‘HPTN 071 (PopART) at CROI 2017: HPTN 071 (PopART) at CROI 2017: Mid-Study Successes and Challenges’ [pdf]
  23. ^ a b UNAIDS (2016) 'Prevention Gap Report'[pdf]
  24. ^ "Antiretroviral Therapy Is the Biggest Expense in HIV Care". POZ. 2010-09-23. Retrieved 2018-11-07.
  25. ^ Schackman, Bruce R.; Fleishman, John A.; Su, Amanda E.; Berkowitz, Bethany K.; Moore, Richard D.; Walensky, Rochelle P.; Becker, Jessica E.; Voss, Cindy; Paltiel, A. David (April 2015). "The Lifetime Medical Cost Savings from Preventing HIV in the United States". Medical care. 53 (4): 293–301. doi:10.1097/MLR.0000000000000308. ISSN 0025-7079. PMC 4359630. PMID 25710311.{{cite journal}}: CS1 maint: PMC format (link)
  26. ^ Ford, Nathan; Calmy, Alexandra; Mills, Edward J (2011). "The first decade of antiretroviral therapy in Africa". Globalization and Health. 7 (1): 33. doi:10.1186/1744-8603-7-33. ISSN 1744-8603. PMC 3192657. PMID 21958478.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  27. ^ "Opinion | H.I.V. Drugs Cost $75 in Africa, $39,000 in the U.S. Does It Matter?". Retrieved 2018-11-07.
  28. ^ "Antiretroviral HIV Drugs: Side Effects and Adherence". Healthline. Retrieved 2018-11-07.
  29. ^ "Adverse Effects of ARV Limitations to Treatment Safety and Efficacy Adult and Adolescent ARV". AIDSinfo. Retrieved 2018-11-07.
  30. ^ "Adverse Effects of Antiretroviral Drugs". hivinsite.ucsf.edu. Retrieved 2018-11-07.
  31. ^ Renju, Jenny; Moshabela, Mosa; McLean, Estelle; Ddaaki, William; Skovdal, Morten; Odongo, Fred; Bukenya, Dominic; Wamoyi, Joyce; Bonnington, Oliver (2017-07-01). "'Side effects' are 'central effects' that challenge retention in HIV treatment programmes in six sub-Saharan African countries: a multicountry qualitative study". Sex Transm Infect. 93 (Suppl 3): e052971. doi:10.1136/sextrans-2016-052971. ISSN 1368-4973. PMID 28736390.
  32. ^ Rosenberg, Tina. "Look at Brazil". Retrieved 2018-11-07.
  33. ^ Achappa, Basavaprabhu; Madi, Deepak; Bhaskaran, Unnikrishnan; Ramapuram, John T; Rao, Satish; Mahalingam, Soundarya (March 2013). "Adherence to Antiretroviral Therapy Among People Living with HIV". North American Journal of Medical Sciences. 5 (3): 220–223. doi:10.4103/1947-2714.109196. ISSN 2250-1541. PMC 3632027. PMID 23626959.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  34. ^ Shelton, James D. (2011-12-23). "ARVs as HIV Prevention: A Tough Road to Wide Impact". Science. 334 (6063): 1645–1646. doi:10.1126/science.1212353. ISSN 0036-8075. PMID 22194560.
  35. ^ a b Stadeli, Kathryn M; Richman, Douglas D (2012). "Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review". Antiviral Therapy. 18 (1): 115–123. doi:10.3851/IMP2437. ISSN 1359-6535.
  36. ^ "HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study". The Lancet Infectious Diseases. 11 (10): 750–759. 2011-10-01. doi:10.1016/S1473-3099(11)70149-9. ISSN 1473-3099.
  37. ^ Hamers, Raph L; Rinke de Wit, Tobias F; Holmes, Charles B (October 2018). "HIV drug resistance in low-income and middle-income countries". The Lancet HIV. 5 (10): e588–e596. doi:10.1016/S2352-3018(18)30173-5. ISSN 2352-3018.
  38. ^ "HIV Drug Resistance Climbs in Low- to Middle-Income Countries". MD Magazine. Retrieved 2018-11-07.
  39. ^ a b Wainberg, Mark A. (1998-06-24). "Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance". JAMA. 279 (24): 1977. doi:10.1001/jama.279.24.1977. ISSN 0098-7484.
  40. ^ WHO (2016) ‘Global Report on Early Warning Indicators of HIV Drug Resistance’ [pdf]
  41. ^ "Factors Affecting Adherence to Antiretroviral Therapy in People Living with HIV/AIDS". Journal of the Association of Nurses in AIDS Care. 14 (4): 37–45. 2003-07-01. doi:10.1177/1055329003252424. ISSN 1055-3290.
  42. ^ Kim, Jungmee; Lee, Eunyoung; Park, Byung-Joo; Bang, Ji Hwan; Lee, Jin Yong (2018-02-16). "Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009–2016: A nationwide study". Scientific Reports. 8 (1). doi:10.1038/s41598-018-21081-x. ISSN 2045-2322.
  43. ^ "From Access to Adherence: The Challenges of Antiretroviral Treatment - Studies from Botswana, Tanzania and Uganda, 2006: Factors that facilitate or constrain adherence to antiretroviral therapy among adults at four public health facilities in Botswana: a pre-intervention study: Chapter 4: Quantitative results: 4.4 Factors affecting adherence to ART". apps.who.int. Retrieved 2018-11-07.
  44. ^ "Starting antiretroviral treatment for HIV". AVERT. 2015-06-23. Retrieved 2018-11-07.
  45. ^ "What to Start Adult and Adolescent ARV". AIDSinfo. Retrieved 2018-11-07.
  46. ^ Meintjes, Graeme; Moorhouse, Michelle A.; Carmona, Sergio; Davies, Natasha; Dlamini, Sipho; Van Vuuren, Cloete; Manzini, Thandekile; Mathe, Moeketsi; Moosa, Yunus (2017-07-14). "Adult antiretroviral therapy guidelines 2017". Southern African Journal of HIV Medicine. 18 (1). doi:10.4102/sajhivmed.v18i1.776. ISSN 2078-6751.
  47. ^ Gardner, Edward M.; McLees, Margaret P.; Steiner, John F.; Del Rio, Carlos; Burman, William J. (2011-03-15). "The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 52 (6): 793–800. doi:10.1093/cid/ciq243. ISSN 1537-6591. PMC 3106261. PMID 21367734.{{cite journal}}: CS1 maint: PMC format (link)
  48. ^ AIDSinfo (2014) 'Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents'
  49. ^ "Overview of the Global Fund to Fight AIDS, Tuberculosis and Malaria". Center For Global Development. Retrieved 2018-11-04.
  50. ^ "The U.S. & The Global Fund to Fight AIDS, Tuberculosis and Malaria". The Henry J. Kaiser Family Foundation. 2018-05-15. Retrieved 2018-11-04.
  51. ^ "HIV and AIDS". www.theglobalfund.org. Retrieved 2018-11-04.
  52. ^ "Overview of the President's Emergency Plan for AIDS Relief (PEPFAR)". Center For Global Development. Retrieved 2018-10-25.
  53. ^ "The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)". The Henry J. Kaiser Family Foundation. 2017-12-19. Retrieved 2018-11-04.
  54. ^ "PEPFAR". HIV.gov. Retrieved 2018-11-04.
  55. ^ "Latest PEPFAR Program Results". www.pepfar.gov. Retrieved 2018-11-04.
  56. ^ Research, Center for Drug Evaluation and. "Generic Drugs - Generic Drug Facts". www.fda.gov. Retrieved 2018-11-08.
  57. ^ Berwick, Donald (2002-01-26). ""We all have AIDS": case for reducing the cost of HIV drugs to zero". BMJ : British Medical Journal. 324 (7331): 214–218. ISSN 0959-8138. PMC 1122133. PMID 11809645.{{cite journal}}: CS1 maint: PMC format (link)
  58. ^ Martin, Erika G.; Schackman, Bruce R. (2018-01-25). "Treating and Preventing HIV with Generic Drugs — Barriers in the United States". New England Journal of Medicine. 378 (4): 316–319. doi:10.1056/nejmp1710914. ISSN 0028-4793.
  59. ^ Rosenberg, Tina. "Look at Brazil". Retrieved 2018-11-07.
  60. ^ a b "Opinion | H.I.V. Drugs Cost $75 in Africa, $39,000 in the U.S. Does It Matter?". Retrieved 2018-11-07.
  61. ^ "Out of Sight, Out of Mind: Exploring India's HIV Epidemic". Pulitzer Center. 2016-07-03. Retrieved 2018-11-07.
  62. ^ "HIV treatment is costly, especially for the sickest patients". Retrieved 2018-11-08.
  63. ^ Farmer, Paul; Léandre, Fernet; Mukherjee, Joia S; Claude, Marie Sidonise; Nevil, Patrice; Smith-Fawzi, Mary C; Koenig, Serena P; Castro, Arachu; Becerra, Mercedes C (August 2001). "Community-based approaches to HIV treatment in resource-poor settings". The Lancet. 358 (9279): 404–409. doi:10.1016/S0140-6736(01)05550-7. ISSN 0140-6736.
  64. ^ Farmer, P.; Léandre, F.; Mukherjee, J.; Gupta, R.; Tarter, L.; Kim, J. Y. (2001). "Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy)". Bulletin of the World Health Organization. 79 (12): 1145–1151. ISSN 0042-9686. PMC 2566712. PMID 11799447.{{cite journal}}: CS1 maint: PMC format (link)
  65. ^ Grimsrud, Anna; Lesosky, Maia; Kalombo, Cathy; Bekker, Linda-Gail; Myer, Landon. "Community-based Adherence Clubs for the management of stable antiretroviral therapy patients in Cape Town, South Africa". JAIDS Journal of Acquired Immune Deficiency Syndromes: 1. ISSN 1525-4135.
  66. ^ Walensky, Rochelle P.; Ross, Eric L.; Kumarasamy, Nagalingeswaran; Wood, Robin; Noubary, Farzad; Paltiel, A. David; Nakamura, Yoriko M.; Godbole, Sheela V.; Panchia, Ravindre (2013-10-31). "Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples". New England Journal of Medicine. 369 (18): 1715–1725. doi:10.1056/nejmsa1214720. ISSN 0028-4793. PMC 3913536. PMID 24171517.{{cite journal}}: CS1 maint: PMC format (link)
  67. ^ Freedberg, Kenneth A.; Losina, Elena; Weinstein, Milton C.; Paltiel, A. David; Cohen, Calvin J.; Seage, George R.; Craven, Donald E.; Zhang, Hong; Kimmel, April D. (2001-03-15). "The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease". New England Journal of Medicine. 344 (11): 824–831. doi:10.1056/nejm200103153441108. ISSN 0028-4793.
  68. ^ Sanders, Gillian D.; Bayoumi, Ahmed M.; Sundaram, Vandana; Bilir, S. Pinar; Neukermans, Christopher P.; Rydzak, Chara E.; Douglass, Lena R.; Lazzeroni, Laura C.; Holodniy, Mark (2005-02-10). "Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy". New England Journal of Medicine. 352 (6): 570–585. doi:10.1056/nejmsa042657. ISSN 0028-4793.
  69. ^ McCormack, S., et al (2014) ‘Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial’ The Lancet 387(10013):53-60
  70. ^ San Francisco Department of Public Health, Population Health Division (2015) 'HIV Epidemiology Annual Report 2014'
  71. ^ Grant, Robert M.; Lama, Javier R.; Anderson, Peter L.; McMahan, Vanessa; Liu, Albert Y.; Vargas, Lorena; Goicochea, Pedro; Casapía, Martín; Guanira-Carranza, Juan Vicente (2010-12-30). "Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men". New England Journal of Medicine. 363 (27): 2587–2599. doi:10.1056/nejmoa1011205. ISSN 0028-4793. PMC 3079639. PMID 21091279.{{cite journal}}: CS1 maint: PMC format (link)
  72. ^ "PrEP | HIV Basics | HIV/AIDS | CDC". www.cdc.gov. 2018-11-01. Retrieved 2018-11-07.
  73. ^ Paltiel, A. David; Freedberg, Kenneth A.; Scott, Callie A.; Schackman, Bruce R.; Losina, Elena; Wang, Bingxia; Seage, George R.; Sloan, Caroline E.; Sax, Paul E. (2009-03-15). "HIV Pre-exposure Prophylaxis (PrEP) in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-effectiveness". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 48 (6): 806–815. doi:10.1086/597095. ISSN 1058-4838. PMC 2876329. PMID 19193111.{{cite journal}}: CS1 maint: PMC format (link)
  74. ^ Vissers, Debby C. J.; Voeten, Hélène A. C. M.; Nagelkerke, Nico J. D.; Habbema, J. Dik F.; de Vlas, Sake J. (2008-05-07). "The Impact of Pre-Exposure Prophylaxis (PrEP) on HIV Epidemics in Africa and India: A Simulation Study". PLoS ONE. 3 (5). doi:10.1371/journal.pone.0002077. ISSN 1932-6203. PMC 2367053. PMID 18461185.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  75. ^ UNAIDS (2015) ‘Oral pre-exposure prophylaxis: putting a new choice in context’
  76. ^ Abdool Karim, S. et al (2010) ‘Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women’ Science 329(5996):1168-1174
  77. ^ World Health Organization (WHO) (2015) 'Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV'
  78. ^ World Health Organization (WHO) (2015) 'Policy brief: WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP)'
  79. ^ Henderson, D.K. and Gerberding, J.L. (1989) 'Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis' The Journal of Infectious Diseases 160(2):321-327
  80. ^ Smith, D.K. et al (2005) 'Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States' Morbidity and Mortality Weekly Report 54(2):1-20
  81. ^ Cardo, D.M. et al (1997) 'A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure' The New England Journal of Medicine 337:1485-1490
  82. ^ British HIV Association (BHIVA) (2014, 10 September) 'Change to the recommended regimen for post-exposure prophylaxis (PEP)'
  83. ^ Sultan, Binta; Benn, Paul; Waters, Laura (2014-10-24). "Current perspectives in HIV post-exposure prophylaxis". HIV/AIDS (Auckland, N.Z.). 6: 147–158. doi:10.2147/HIV.S46585. ISSN 1179-1373. PMC 4216036. PMID 25368534.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  84. ^ "PEP | HIV Basics | HIV/AIDS | CDC". www.cdc.gov. 2018-07-23. Retrieved 2018-11-07.
  85. ^ "Post-exposure prophylaxis after non-occupational HIV... : AIDS". LWW. Retrieved 2018-11-07.
  86. ^ "Anti-HIV drugs - Single-tablet regimens". Retrieved 2018-11-03.
  87. ^ Astuti, Noemi; Maggiolo, Franco (June 2014). "Single-Tablet Regimens in HIV Therapy". Infectious Diseases and Therapy. 3 (1): 1–17. doi:10.1007/s40121-014-0024-z. ISSN 2193-8229. PMC 4108118. PMID 25134808.{{cite journal}}: CS1 maint: PMC format (link)
  88. ^ Truong, William R.; Schafer, Jason J.; Short, William R. (January 2015). "Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection". Pharmacy and Therapeutics. 40 (1): 44–55. ISSN 1052-1372. PMC 4296592. PMID 25628507.{{cite journal}}: CS1 maint: PMC format (link)
  89. ^ Margolis, David A; Gonzalez-Garcia, Juan; Stellbrink, Hans-Jürgen; Eron, Joseph J; Yazdanpanah, Yazdan; Podzamczer, Daniel; Lutz, Thomas; Angel, Jonathan B; Richmond, Gary J (September 2017). "Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial". The Lancet. 390 (10101): 1499–1510. doi:10.1016/S0140-6736(17)31917-7. ISSN 0140-6736.
  90. ^ "Swapping daily pills for monthly shots could transform HIV treatment and prevention". Science | AAAS. 2018-08-22. Retrieved 2018-11-07.
  91. ^ Klooster, Gerben van ′t; Hoeben, Eva; Borghys, Herman; Looszova, Adriana; Bouche, Marie-Paule; Velsen, Frans van; Baert, Lieven (2010-05-01). "Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation". Antimicrobial Agents and Chemotherapy. 54 (5): 2042–2050. doi:10.1128/AAC.01529-09. ISSN 0066-4804. PMID 20160045.
  92. ^ Spreen, William R.; Margolis, David A.; Pottage, John C. (November 2013). "Long-acting injectable antiretrovirals for HIV treatment and prevention". Current Opinion in HIV and AIDS. 8 (6): 565–571. doi:10.1097/COH.0000000000000002. ISSN 1746-630X. PMC 3815009. PMID 24100877.{{cite journal}}: CS1 maint: PMC format (link)
  93. ^ "Swapping daily pills for monthly shots could transform HIV treatment and prevention". Science | AAAS. 2018-08-22. Retrieved 2018-10-30.
  94. ^ Balzarini, Jan; Van Damme, Lut (March 2007). "Microbicide drug candidates to prevent HIV infection". The Lancet. 369 (9563): 787–797. doi:10.1016/S0140-6736(07)60202-5. ISSN 0140-6736.
  95. ^ a b "Nanotechnology-based systems for the treatment and prevention of HIV/AIDS". Advanced Drug Delivery Reviews. 62 (4–5): 458–477. 2010-03-18. doi:10.1016/j.addr.2009.11.017. ISSN 0169-409X.
  96. ^ "Microbicides". HIV.gov. Retrieved 2018-11-07.
  97. ^ Naswa, Smriti; Marfatia, Y. S.; Prasad, T. L. N. (2012). "Microbicides and HIV: A Review and an update". Indian Journal of Sexually Transmitted Diseases and AIDS. 33 (2): 81–90. doi:10.4103/2589-0557.102098. ISSN 2589-0557. PMC 3505301. PMID 23188931.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  98. ^ a b Shattock, Robin J.; Rosenberg, Zeda (February 2012). "Microbicides: Topical Prevention against HIV". Cold Spring Harbor Perspectives in Medicine. 2 (2). doi:10.1101/cshperspect.a007385. ISSN 2157-1422. PMC 3281595. PMID 22355798.{{cite journal}}: CS1 maint: PMC format (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Treatment_as_prevention&oldid=868100782"